Back to search results

Proton Therapy for Esophageal Cancer

This study is looking at a new way to treat esophageal cancer using proton radiation along with chemotherapy. The chemotherapy drugs being tested are carboplatin and paclitaxel, which are given before surgery. Researchers want to see if this combination improves overall survival for people with certain types of esophageal cancer that can be removed by surgery. You might be able to join if you have squamous cell or adenocarcinoma of the esophagus that meets specific staging criteria. The study is currently unclear on its recruitment status and aims to enroll 38 participants.

Study design
This is a phase II interventional study, meaning it tests a new treatment approach in a small group of people. It plans to enroll 38 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 3 months after treatment to assess overall survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01684904

Proton Therapy for Esophageal Cancer

Recruiting
NAAges 18+InterventionalTreatment
Loma Linda University
~38 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Proton radiation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer
Measured over The major analysis for reporting the initial results of treatment will be undertaken when each patient has been potentially followed for a minimum of 3 months

Conditions

Esophagus Cancer

Explore related trials

Esophageal Carcinoma

NCT01684904

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Loma Linda University Medical Center

    Loma Linda, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Who to contact

Proton Referral Office First call: Referral Office intake personnel
909-558-4288 or 1 800 PROTONS
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically confirmed primary squamous cell or adenocarcinoma of the esophagus that involves the mid, distal or esophagogastric junction. The cancer may involve the stomach up to 5 cm.
Endoscopy with biopsy
Stage T1N102, T2-3N0-2 according to the American Joint Committee on Cancer (AJCC) 7th edition staging, based upon the following minimum diagnostic work-up:
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
Platelets ≥ 100,000 cell/mm3
Hemoglobin ≥ 8.0 g/dl (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)

What this trial measures

  • To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancerThe major analysis for reporting the initial results of treatment will be undertaken when each patient has been potentially followed for a minimum of 3 months